Filtered By:
Drug: Beta-Blockers

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 494 results found since Jan 2013.

Sildenafil Administration Improves Right Ventricular Function on 4D Flow MRI in Young Adults Born Premature
CONCLUSIONS: Despite reduced right atrial workload, metoprolol significantly depressed overall cardiac systolic function. Sildenafil, however, increased CI and improved RV function, as quantified by the direct flow fraction. The preterm heart appears dependent on HR, but sensitive to RV afterload manipulations.PMID:33861148 | DOI:10.1152/ajpheart.00824.2020
Source: American Journal of Physiology. Heart and Circulatory Physiology - April 16, 2021 Category: Physiology Authors: Philip A Corrado Gregory P Barton Christopher J Fran çois Oliver Wieben Kara N Goss Source Type: research

Certain high blood pressure medications may alter heart risk in people with HIV
(American Heart Association) Some blood pressure medications altered the likelihood of subsequent heart disease, stroke or heart failure in a study of veterans who have HIV (human immunodeficiency virus).Patients with HIV prescribed beta-blockers were more likely to develop cardiovascular disease compared to patients taking other blood pressure medications, even if their blood pressure was well controlled. All other classes of hypertensive medications showed no differences regarding cardiovascular risk outcomes.
Source: EurekAlert! - Medicine and Health - April 5, 2021 Category: International Medicine & Public Health Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Effect of Beta-Blockers on Stroke Outcome: A Meta-Analysis
Source: Clinical Epidemiology - March 15, 2021 Category: Epidemiology Tags: Clinical Epidemiology Source Type: research

Guideline Adherence and Associated Outcomes in the Treatment of Type 2 Diabetes Mellitus Patients With an Incident Cardiovascular Comorbidity: An Analysis Based on a Large German Claims Dataset
ConclusionOnly a minority of patients with T2DM and an incident CV comorbidity receive a treatment fully adherent with guideline recommendations. This may contribute to high mortality rates in this population in clinical practice.
Source: Diabetes Therapy - March 12, 2021 Category: Endocrinology Source Type: research

Sex-based outcomes after coronary artery bypass grafting.
CONCLUSIONS: Sex was not an independent predictor of long-term MACE after CABG in this population-based cohort study. Men had however higher long-term all-cause mortality and women higher risk of myocardial infarction. Long-term outcomes should be accounted for when considering sex as a risk factor for CABG. PMID: 33484674 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - January 20, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Kytö V, Sipilä J, Tornio A, Rautava P, Gunn J Tags: Ann Thorac Surg Source Type: research

Trends in optimal medical therapy at discharge and clinical outcomes in patients with acute coronary syndrome in Thailand.
CONCLUSIONS: The five-drugs comprising OMT were associated with a reduction in all-cause mortality and MACE in patients with ACS. Nevertheless, OMT prescribing remains underused and could be enhanced in the real-world setting. PMID: 33455848 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - January 14, 2021 Category: Cardiology Authors: Wongsalap Y, Kengkla K, Poolpun D, Saokaew S Tags: J Cardiol Source Type: research

Incidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classes.
Authors: Harrison PJ, Colbourne L, Luciano S Abstract Antihypertensive drugs (AHTs) are associated with lowered risks of neurodegenerative diseases and stroke. However, the relative risks associated with different AHT classes are unclear. Using an electronic health record network with 34 million eligible patients, we compared rates of these disorders over a 2-year period, in propensity score-matched cohorts of people taking calcium channel blockers (CCBs) compared with those taking other AHT classes. CCBs were associated with a higher incidence of all disorders compared with renin-angiotensin system agents, and a h...
Source: The British Journal of Psychiatry for Mental Science - January 9, 2021 Category: Psychiatry Tags: Br J Psychiatry Source Type: research

Treatment of migraine in patients with CADASIL: A systematic review and meta-analysis
Conclusions Migraine in CADASIL remains a formidable therapeutic challenge, with patients often tried on several medications. Antimigraine prophylaxis with beta-blockers may be contraindicated relative to other common therapies in CADASIL. Controlled studies are needed to rigorously evaluate the safety and efficacy of antimigraine therapies in this population.
Source: Neurology Clinical Practice - December 7, 2020 Category: Neurology Authors: Glover, P. A., Goldstein, E. D., Badi, M. K., Brigham, T. J., Lesser, E. R., Brott, T. G., Meschia, J. F. Tags: Migraine, Other cerebrovascular disease/ Stroke, All Cerebrovascular disease/Stroke, Clinical trials Systematic review/meta analysis, CADASIL Source Type: research